Solid Biosciences (SLDB) Stock Price, News & Analysis

Company Overview

Solid Biosciences Inc. (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for neuromuscular and cardiac diseases. The company combines gene therapy, genetic medicine and manufacturing technologies to design treatments intended to address the underlying causes of serious inherited disorders.

Solid’s lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a progressive genetic disease that causes muscle degeneration. The company is also advancing SGT-501, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, a rare inherited heart condition. These products remain in clinical development and are not approved for commercial use.

Founded in 2013, Solid Biosciences initially focused primarily on Duchenne muscular dystrophy and has since expanded its research into additional neuromuscular and cardiac conditions. The company broadened its gene therapy capabilities through the acquisition of AavantiBio in 2022. Solid is headquartered in Cambridge, Massachusetts, and conducts research and clinical development activities primarily in the United States and through international clinical collaborations. Bo Cumbo serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $8.56 to $8.96
• 50-Day Range: $7.83 to $10.42
• 52-Week Range: $3.79 to $11.45
• Volume: 1.31 million shs
• Average Volume: 1.08 million shs
• Market Capitalization: $956.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.69
• Consensus Rating: Moderate Buy

Solid Biosciences Stock Analysis - MarketRank™

Solid Biosciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 337th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Solid Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Solid Biosciences has a consensus price target of $18.69, representing about 109.6% upside from its current price of $8.92.

Amount of Analyst Coverage

Solid Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Solid Biosciences are expected to decrease in the coming year, from ($1.67) to ($1.75) per share.

Price to Book Value per Share Ratio

Solid Biosciences has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.70% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 18.91, which indicates bearish sentiment.

Change versus previous month

Short interest in Solid Biosciences has recently decreased by 1.42%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solid Biosciences does not currently pay a dividend.

Dividend Growth

Solid Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.74

News Sentiment

Solid Biosciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Solid Biosciences this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for SLDB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solid Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.66% of the stock of Solid Biosciences is held by insiders.

Percentage Held by Institutions

81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SLDB
• CIK: 1707502
• Web: www.solidbio.com
• Phone: (617) 337-4680
• Fax: N/A
• Employees: 121
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Solid Biosciences: $18.69
• High Price Target: $26.00
• Low Price Target: $9.00
• Potential Upside/Downside: +109.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$174.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.35%
• Return on Assets: -60.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.82
• Quick Ratio: 13.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.28 per share
• Price / Book: 3.91

Miscellaneous

• Outstanding Shares: 107,220,000
• Free Float: 104,373,000
• Market Cap: $956.40 million
• Optionable: Optionable
• Beta: 2.44